Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study

Jignesh Prajapati1 · Rohit Patel2 · Priyashi Rao1 · Meenu Saraf2 · Rakesh Rawal1,3 · Dweipayan Goswami2

Received: 31 January 2022 / Accepted: 31 March 2022 / Published online: 8 April 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Coronavirus disease 2019 (COVID-19) persists and shook the global population where the endgame to this pandemic is brought on by developing vaccines in record-breaking time. Nevertheless, these vaccines are far from perfect where their efficiency ranges from 65 to 90%; therefore, vaccines are not the one only solution to overcome this situation, and apart from administration of vaccines, the scientific community is at quest for finding alternative solutions to incumber SARS-CoV-2 infection. In this study, our research group is keen on identifying a bioactive molecule that is independent in its mode of action from existing vaccines which can potentially target the SARS-CoV-2 virus replicative efficacy. Papain-like protease (PLpro) and main protease (Mpro) are the most lucrative targets of COVIDs against which the drugs can be developed, as these proteases play a vital role in the replication and development of viral particles. Researchers have modelled a compound such as GRL0617 and X77 as an inhibitor of Mpro and PLpro, respectively, but use of these compounds has several limitations on hosts like toxicity and solubility. Under the current study by deploying rigorous computational assessments, pool of microbial secondary metabolites was screened and handpicked to search a structural or functional analogue of GRL0617 and X77, with an idea to identify a compound that can serve as dual inhibitor for both PLpro and Mpro. From the manually curated database of known antiviral compounds from fungal origin, we found cytonic acids A and B to potentially serve as dual inhibitor of PLpro and Mpro.

Keywords SARS-CoV-2 · Antiviral · Papain-like protease (PLpro) · Main protease (Mpro) · Endophytes · Molecular dynamics simulations

Introduction
Coronavirus disease 2019 (COVID-19) manifests a range of physiological conditions on host, ranging from being entirely asymptomatic to minor influenza to cough, cold and sore throat to manifestations like acute respiratory distress, pneumonia and lung damage to even death [1, 2]. During the first wave of the infection, all affected countries endorsed various precautionary measures, including a total or partial lockdown of residents, implementation of social distancing, wearing of face masks and frequent hand sanitization. More significantly, individuals did not follow the prevention measures precisely and the number of affected individuals changed relying upon how powerful the prevention measures were. Additionally, these recommended measures have been headed to the detriment of the economy and more crucially, these severe control measures alone are not viable enough to stop the COVID-19 pandemic. This is vividly observed in both developing and developed countries, where people were hit by a third wave of coronavirus infection due to the lack of antiviral medication or vaccination, and as a result, the scientists from around the world are prompted to find effective medications and vaccines for COVID-19 treatment and prevention [1, 3].
In the last 1 year, COVID-19 vaccines are being developed using various strategies, executed from a typical inactivated and live-attenuated vaccines to more innovative messenger RNA (mRNA) and DNA technologies, like subunit vaccines [4–6]. For instance, BBV152 is a classical inactivated whole virion vaccine, while mRNA-1273 and mRNA-BNT162b2 are mRNA-based vaccines that target SARS-CoV-2 spike protein [5]. Herd immunity may hypothetically be achieved because of the high incidence of protection from infection after vaccination; however, there is no reliable assurance to it. Besides, there are yet various vaccination-related inquiries that are presently unaddressed, which include the length of a vaccination preventive effects and cross-protection against variants of interests (VOI) and variants of concerns (VOC) (Alpha, Beta, Gamma, Delta, Delta Plus, Epsilon, Eta, Theta, Iota, Kappa and Lambda), particularly the new VOC, Omicron (B.1.1.529) [7]. Mortality related with COVID-19 is fairly reducing as vaccination rates rise, but the list of variants is increasing as new mutations continue to evolve, challenging the whole vaccine regime [8].

While the vaccination drive continues, another promising strategy would be to foster new drugs that are compelling against SARS-CoV-2. Virus replication necessitates a certain set of functional and structural proteins. Malfunctioning or inhibition of these proteins can slow or stop infection or can also halt viral multiplication, culminating its spread, which is desired by researchers. As a result, medicines that can regulate the accessibility of these proteins should be pursued. SARS-CoV-2 is a 29-kb RNA genome that encodes two large overlapping polyprotein precursors (pp1a and pp1ab); these two translated stretches of inactive proteins are then treated upon by PLpro and Mpro which cleave pp1a and pp1b into various small fragments where each fragment serves as active viral protein that functions in replication, transcription and assembly of the virus nuclear material into the capsid protein coat (Fig. 1). Consequently, inhibiting these proteases may have a considerable impact on the viral machinery and the overall rate of viral infection. Scientists around the globe have well considered these proteases (Mpro and PLpro) as important drug targets for developing new

Fig. 1 Representation for addressing role of viral proteases PLpro and Mpro to produce non-structural proteins participating in viral replication and transcription
medications or repurposing already existing drugs [9, 10], as inhibiting these proteases directly halts the functioning and replication of SARS-CoV-2, making the virus ineffective [11, 12].

Bioactive and natural products derived from plants, microorganisms and animals are most often recommended to treat infectious disorders [13, 14]. The term ‘endophytes’ signifies microorganisms living inside the tissue of plant with imparting mutualistic behaviour. Considering the published literature, endophytes could be an untapped reservoir full of diverse resources of bioactive compounds [15]. Identifying a compound from reservoir that can block PLpro and Mpro is the rationale of this research which in itself is a challenging as well as exciting avenue.

The likelihood of discovering novel inhibitors using microbial databases of natural compounds has increased as computer hardware and software technologies have progressed. Several investigations have used computer-aided drug designing (CADD) tools where in its pipeline first the compounds are screened by ‘molecular docking’ approach which identifies compounds that can interact with important amino acids in the active site of protein, followed by ‘molecular dynamics (MD) simulations’ that perform a real-time simulation of interaction between screened ligand and protein under virtual physiological environment, and a blend of advanced in silico approaches to discover natural bioactive compounds from large databases that could be used as possible lead compounds [16–19]. The novelty of this piece of research work lies in the fact that antiviral metabolites from endophytic origin are very less investigated against the SARS-CoV-2 proteases (Mpro and PLpro), the reason being the scarcity of published literature and unavailability of off-the-shelf databases. To date, there are several secondary bioactive active metabolites identified from endophytes possessing ability to inhibit viral proteases, and they are emodin, α-hydroxyemodin, (+)-sclerotiorin, phomopsone B and phomopsone C [20–23], but such study for proteases of SARS-CoV-2 is lacking which serves as a research loophole which we are targeting in this research piece.

For this study, we have nit-picked literary evidence of antiviral compounds obtained from endophytic microorganisms and prepared a library to virtually screen them against SARS-CoV-2 Mpro and PLpro, as a dual inhibitor. This is done to ensure the optimal potential of the ligand library to act simultaneously on the activity of both proteases altogether. After screening the entire library, cytonic acids A and B were identified as PLpro and Mpro dual protease inhibitor. Under this research piece, screening hierarchy followed the use of protein–ligand docking, followed by pharmacophore hypothesis generation, which was then followed by absorption–distribution–metabolism–excretion–toxicity (ADMET) profiling and protein–ligand binding Gibbs free energy change calculation through molecular mechanics generalised Born surface area (MM-GBSA) assessment. Additionally, the dynamic nature of protein–ligand contacts was analysed using MD simulations. The simulation was undertaken for cytonic acid derivatives and control compounds for a 100-ns-long timescale. We predict that cytonic acids A and B as a dual-target therapeutic approach for COVID-19 could be more effective and would substantially reduce the use of combinational drugs as well as prevent the multi-drug dose load on the already immune-compromised and weakened host system.

**Materials and methods**

**Protein preparation**

PLpro protein of SARS-CoV-2 (PDB ID: 7CMD) co-crystalized form with GRL0617 and Mpro of SARS-CoV-2 (PDB ID: 6W63) co-crystalized form with X77 were retrieved from the protein databank (PDB) [24–26]. Here, GRL0617 and X77 are the known inhibitors for respective proteins and were used as reference. Proteins were imported to Schrödinger Maestro and were prepared in protein preparation wizard of Schrödinger Maestro [27]. In which, the addition of hydrogens was performed, and net state at pH 7.0 was created using Epik. Then, the protein was optimized with PROPKA keeping its parameter as pH = 7.0. On successful completion of these two steps, the minimization was performed using force field OPLS2005.

**Metadata curation for ligand library development**

From the available literature of research articles, the data of endophytic microorganisms and endophytic microorganisms and their bioactive metabolites was manually collected. Based on experimental antiviral effects of metabolites against various viruses such as influenza, H1N1, HIV, HCV, and EV-71, the 45 antiviral compounds were retrieved from published studies. Table I lists the 45 compounds present in the library, along with their isolation sources and bioactivity. All the ligands were retrieved in SDF format and were imported to the Schrödinger Maestro for ligand preparation for docking, where the LipPrep wizard was used, addition of hydrogens was performed, and ligand minimization was performed using force field OPLS2005. The files were exported after ligand minimization and subsequently used for molecular docking.
| Sr. no | Secondary metabolite                          | Endophytic organism | Host                  | Location | Virus             | Activity (IC₅₀) | Reference |
|-------|-----------------------------------------------|---------------------|-----------------------|----------|-------------------|----------------|-----------|
| 1     | 6-O-Demethyl-4-dehydroxyaltersolanol A        | Nigrospora sp. YE3033 | Aconitum carmichaelii | China    | H1N1 influenza A | 2.59 ± 1.22 µg/mL | [61]     |
| 2     | 4-Dehydroxyaltersolanol A                    |                     |                       |          |                   |                |           |
| 3     | Altersolanol B                               |                     |                       |          |                   |                |           |
| 4     | Chermesinone B                               |                     |                       |          |                   |                |           |
| 5     | Emolin                                        | Aspergillus versicolor | Halimeda opuntia      | Egypt    | HCV protease     | 22.5 ± 1.6 µg/mL | [20]     |
| 6     | 2,11-Dideoxyrhizoxin                          | Fusarium equiseti   | Padina pavonica       | Egypt    | HCV protease     | 10.71 ± 2.3 µM | [22]     |
| 7     | 17-Demethyl-2,11-dideoxyrhizoxin              | Penicillium scroto- | Garcinia atrorvir-   | Thailand | HIV-1 integrase  | 14.5 µg/mL    | [23]     |
| 8     | 17-Demethyl-2,11-dideoxyrhizoxin              |                      |                       |          | HIV-1 protease   | 62.7 µg/mL    |           |
| 9     | Cordycepin                                    | Fusarium equiseti   | Padina pavonica       | Egypt    | HCV protease     | 22.3 µM       | [22]     |
| 10    | Cyclic tetrapeptidecyclclo-[phenyl alanyl-pro-leu-pro] |                     |                       |          |                   |                |           |
| 11    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                | 29.4 µM   |
| 12    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                | 34.4 µM   |
| 13    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                |           |
| 14    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                |           |
| 15    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                |           |
| 16    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                |           |
| 17    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                |           |
| 18    | 17-Demethyl-2,11-dideoxyrhizoxin              |                     |                       |          |                   |                |           |
| 19    | Emerimidine A                                 | Emericella sp. (HK-ZJ) | Aegiceras cornicu-   | China    | H1N1 influenza A | 42.07 µg/mL    | [63]     |
| 20    | Emerimidine B                                 |                     | lumatum               |          |                   |                |           |
| 21    | Chloropupukeananin                            | Pestalotiopsis fici | Unknown               | China    | HIV-1            | 14.6 µM       | [64]     |
| 22    | Periconiasin G                                | Periconia sp. F-31  | Anmona muricata       | China    | HIV-1            | 67.0 µM       | [65]     |
| 23    | Aspergilline A                                | Aspergillus versicolor | Paris polyphylla     | China    | Tobacco mosaic   | 56.4 ± 3.8 µM | [60]     |
| 24    | Aspergilline B                                |                     | var. yunnanensis     |          | virus            |                |           |
| 25    | Aspergilline C                                |                     |                       |          |                   |                |           |
| 26    | Aspergilline D                                |                     |                       |          |                   |                |           |
| 27    | Aspergilline E                                |                     |                       |          |                   |                |           |
| 28    | Xiamycin                                      | Streptomyces sp. F32027 | Quercus sp.         | UK       | CMV protease     | 43 µM         | [58]     |
| 29    | Xiamycin methyl ester                         |                     |                       |          |                   |                |           |
| 30    | Neosartoryadin A                              | Neosartorya udagowae | Avicennia marina     | China    | H1N1 influenza A | 66 µM         | [68]     |
| 31    | Neosartoryadin B                              |                     |                       |          |                   |                |           |
| 32    | Neosartoryadin C                              |                     |                       |          |                   |                |           |
| 33    | Neosartoryadin D                              |                     |                       |          |                   |                |           |
Generation of E-pharmacophore model

E-pharmacophore hypothesis was generated separately using the crystal structure of (i) SARS-CoV-2 PLpro bound to an inhibitor GRL0617 with a resolution of 2.1 Å (PDB ID: 7CMD) and (ii) SARS-CoV-2 Mpro bound to an inhibitor X77 with a resolution of 2.1 Å (PDB ID: 6W63). During pre-processing of the complex, water molecules within 5 Å distance of the ligand were eliminated from the structure and the minimised complex was used to develop E-pharmacophore model [28, 29]. The E-pharmacophore model was developed using the Phase module (Phase, Schrödinger, LLC, New York, NY, 2021) [30]. For developing hypothesis, default pharmacophore properties like hydrogen bond acceptor (A), hydrogen bond donor (D), aromatic ring (R) and hydrophobicity (H) were mapped. On performing E-pharmacophore, two hypotheses were generated, one for each protein–ligand complex. These E-pharmacophore hypotheses were then used for screening of ligands.

E-pharmacophore-based virtual screening

A E-pharmacophore-based virtual screening was carried out on the prepared library of 45 compounds using the Phase module (Phase, Schrödinger, LLC, New York, NY, 2021) [30]. For developing hypothesis, default pharmacophore properties like hydrogen bond acceptor (A), hydrogen bond donor (D), aromatic ring (R) and hydrophobicity (H) were mapped. On performing E-pharmacophore, two hypotheses were generated, one for each protein–ligand complex. These E-pharmacophore hypotheses were then used for screening of ligands.

Molecular docking

The prepared proteins as shown in earlier step were used for molecular docking. The docking grid at the exact coordinates as ligand GRL0617 in 7CMD for PLpro and X77 in 6W63 for Mpro was prepared using the Glide module of Schrödinger Maestro. The grid for PLpro was developed at the coordinates $X = -34.22$, $Y = 11.61$ and $Z = -30.05$, with the size 10 Å×11 Å×14 Å, while for Mpro, the grid was developed at the coordinates $X = 20.58$, $Y = 18.1$ and $Z = 26.98$, with the size 12 Å×14 Å×15 Å and was prepared. For docking, the prepared ligands so obtained after E-pharmacophore-based screening (15 for PLpro and 18 for Mpro) were used. Moreover, native ligands GRL0617 for PLpro and X77 for Mpro were used as positive controls for docking with respective proteins, PLpro and Mpro. Docking level was set to ‘Extra Precision (XP)’, docking energies in negative values with unit kcal/mol were recorded, and the output file of docked poses was analysed for interactions in BIOVIA Discovery Studio (DS) visualizer. The ligands showing the highest negative binding docking scores and protein interactions were screened for further in silico assays including MM-GBSA and MD simulations.

MM-GBSA calculations

MM-GBSA determines the Gibbs free energy change in kcal/mol that predicts how spontaneous the interaction reaction can be between selected screened ligand and protein. The greater negativity in the values shows more spontaneous reaction. This $\Delta G$ value can be compared for with that of reference native ligand. If the values shown by screened selected ligand are more negative than by the reference ligand, then the binding spontaneity of the screened ligand is stronger than of the reference native ligand [31–34]. MM-GBSA assessment was performed using the Prime module of Schrodinger Maestro making use of OPLS2005 force field. The $\Delta G_{\text{bind}}$ is the overall Gibbs free energy change value of the system, which is also bifurcated further into segments as $\Delta G_{\text{Coulomb}}$—Coulomb energy, $\Delta G_{\text{Bond}}$—hydrogen-bonding correction, $\Delta G_{\text{Lipo}}$—lipophilic energy, $\Delta G_{\text{Pack}}$—pi-pi packing correction, $\Delta G_{\text{vdW}}$—Van der Waals energy, etc.

ADMET analysis

The ADMET properties of the GRL0617 and X77 (as controls) and top screened ligands (test endophytic molecules)
were predicted using the pkCSM—pharmacokinetics server [35] which provides the theoretical values that are obtained by proven animal model turned in to finely tuned algorithms. Values for each of the parameters like water solubility, CaCO₂ permeability, intestinal absorption (human), skin permeability, P-glycoprotein substrate, P-glycoprotein I and II inhibitor, blood–brain barrier (BBB) permeability, central nervous system (CNS) permeability, cytochrome p450 (CYP)2D6 and CYP3A4 substrate, CYP1A2-CYP2C19-CYP2C9-CYP2D6-CYP3A4 inhibitor, renal clearance, AMES toxicity, max. tolerated dose, hERG I and II inhibitor, oral rat acute and chronic toxicity, hepatotoxicity, skin sensitisation, T. pyriformis toxicity and minnow toxicity are obtained for each ligand under study by this assessment. This helps to understand and compare drugs, like properties of screened selected ligands in comparison with the reference molecules.

**MD simulations**

The Desmond module of Schrödinger Maestro was used to perform simulations of SARS-CoV-2 PLpro-ligand and Mpro-ligand complexes. Cytonic acid A and cytonic acid B were having efficient binding energy and proper ADMET profile and both were able to mimic interactions of native ligand with PLpro as well as Mpro; MD simulations were carried out for the following complexes: (I) PLpro-GRL0617, (II) PLpro-cytonic acid A, (III) PLpro-cytonic acid B, (IV) Mpro-X77, (V) Mpro-cytonic acid A and (VI) Mpro-cytonic acid B. For the simulation assessments, the complexes PLpro-GRL0617 and Mpro-X77 were taken as reference controls against which the simulation results of cytonic acid A and cytonic acid B with both the proteins were compared with. For MD simulations, the virtual simulation box was prepared into which complex was placed, and then, the simulation box was filled with water molecules with TIP3P model, after which the ion Na⁺ was placed in the simulation box for neutralisation. MD simulations were performed with NPT ensemble at 300 K and 1.01 bar for 100 ns. Post MD simulation assessments were performed by assessing ligand receptor interaction profiles with respect to time, types and nature; the root mean square deviation (RMSD) and root mean square fluctuation (RMSF) assessments of trajectories were also analysed to evaluate the stability of protein–ligand complexes during the simulations run.

**Results**

**Metadata assessment for ligand library development**

The prepared library for this in silico analysis included specialized nit-picked literary evidenced endophytic compounds having in vitro anti-viral activity observed against influenza, H1N1, HIV, HCV and EV-71 viruses. Forty-five antiviral compounds obtained from endophytic microorganisms were used to virtually screen them against SARS-CoV-2 Mpro and PLpro, as a dual inhibitor. Table 1 contains information on the names of the compounds, their endophyte sources and their antiviral efficacy against particular viruses.

**Structure-based pharmacophore modelling**

Receptor-pharmacophore based on the 3D structure of a target protein can provide detailed and accurate information on ligand interaction attributes. In totality, there are about 8 descriptors used for pharmacophore modelling; amongst which, hydrogen bond donors, acceptors, lipophilic regions and negative and positive ionizable groups along with aromatic rings are the most commonly used descriptors in pharmacophore modelling. For this study, 3D structure–based e-pharmacophores were prepared with the ‘Phase’ module which utilises the receptor–ligand pharmacophore generation procedure and discovered amino acids involved in ligand binding for a co-crystal GRL0617 inhibitor within the binding site of PLpro (Fig. 2a) and for a co-crystal X77 inhibitor within the binding site of Mpro (Fig. 2c). Hydrogen bond acceptor, hydrogen bond donor and pi-pi stacking of aromatic ring were amongst the five key 3D attributes of the generated e-pharmacophore for the evaluated protein. Figure 2b depicts the five 3D pharmacophore characteristics for the PLpro-GRL0617 complex that includes two donor hydrogen bonds, one acceptor hydrogen bond and one aromatic ring sphere, while Fig. 2d depicts the five 3D pharmacophore characteristics for the Mpro-X77 complex, including two acceptor hydrogen bonds and three aromatic ring spheres.

**Pharmacophore-based virtual screening analysis**

The 45 potential anti-viral compounds of endophytes origin (Table 1) were screened using the E-pharmacophore hypothesis created from the GRL0617-PLpro complex and X77-Mpro. The ‘Phase’ screen score and corresponding binding site variables were used to filter these compounds. The Phase screen score is utilised to score and rank the matching compounds. This scoring function assesses both the quantity (if partial matching is permitted) and quality of ligand feature matching, where quality is defined by site, vector and volume scoring components. After the execution of the proposed pharmacophore hypothesis, a total of 15 molecules managed to pass this filter for the PLpro-GRL0617 complex (Table 2) and 18 molecules for the Mpro-X77 complex (Table 3).
Molecular docking analysis

After using Glide’s Receptor Grid Generation tool in Maestro to define the grid box, the minimised 3D molecular structure of the co-crystallised inhibitor GRL0617 was docked into the active site of viral PLpro. The molecular interaction of the co-crystallised inhibitor (GRL0617) with the binding site of the viral protease SARS-CoV-2-PLpro was discovered. In general, hydrophobic interactions induce GRL0617’s binding to SARS-PLpro, which results in protein inhibition. The aromatic rings’ 1-naphthyl moiety frames the primary contact as a pi–pi interaction with Tyr264 and Tyr268, is less exposed to solvent and fits into the cavity at the locus where the leucine at the P4 position is required. Furthermore, the 1-naphthyl moiety

Table 2 Compounds managed to pass PLpro-GRL0167 complex pharmacophore hypothesis using Phase virtual screening

| Entry | Compound name          | Number of sites matched | Matched ligand sites | Phase screen score |
|-------|------------------------|-------------------------|----------------------|-------------------|
| 1     | Stachybogrisphenone B  | 4                       | A(3) D(7) D(8) R(14) R(-) | 1.766             |
| 2     | 4-Dehydroxyaltersolanol A | 4                   | A(5) D(10) D(9) R(13) R(-) | 1.723             |
| 3     | Aspergilline D         | 4                       | A(3) D(10) D(11) R(-) R(17) | 1.717             |
| 4     | Altersolanol B         | 4                       | A(4) D(9) D(8) R(11) R(-) | 1.669             |
| 5     | Aspergilline E         | 4                       | A(3) D(12) D(13) R(-) R(20) | 1.513             |
| 6     | Cytonic acid B         | 4                       | A(4) D(12) D(-) R(21) R(20) | 1.436             |
| 7     | Perilyoyrine           | 4                       | A(1) D(-) D(4) R(6) R(9) | 1.435             |
| 8     | Neosartoryadin A       | 4                       | A(3) D(-) D(8) R(12) R(11) | 1.434             |
| 9     | Asperphenalenone D     | 4                       | A(7) D(13) D(12) R(23) R(-) | 1.419             |
| 10    | Cordycepin             | 4                       | A(4) D(8) D(7) R(-) R(12) | 1.400             |
| 11    | Asperphenalenone A     | 4                       | A(6) D(9) D(8) R(22) R(-) | 1.330             |
| 12    | Cytonic acid A         | 4                       | A(3) D(9) D(-) R(19) R(20) | 1.290             |
| 13    | Altertoxin I           | 4                       | A(1) D(9) D(8) R(-) R(12) | 1.244             |
| 14    | Aspergilline A         | 4                       | A(6) D(9) D(7) R(-) R(15) | 0.528             |
| 15    | Aspergilline C         | 4                       | A(6) D(9) D(7) R(-) R(17) | 0.505             |

Ligands having Phase screen score above 0.5 are screened
interacts with Pro247’s and Pro248’s side chains. The (R)-methyl group at GRL0167’s stereocenter is located inside the protein, between Tyr264 and Thr301 residues, in a small polar region. GRL0617 features a single aromatic ring with NH2 at R3 position, which is positioned at the cavity’s aperture, in addition to the 1-naphthyl moiety. The cavity is polar because of the presence of several polar groups, such as Gln269’s side chain oxygen and Tyr268’s hydroxyl group, which function as hydrogen bond acceptors in the interaction. After pharmacophore screening, a total of 15 microbial metabolites were investigated for molecular docking utilising Schrödinger’s Glide XP lead optimization methodology. Four fungal metabolites of endophytic origin, aspergilline E, cytonic acid A, cytonic acid B and 4-dehydroxyaltersolanol A, produced significant binding energies along with multiple conserved interactions with Tyr268 of SARS-CoV-2-PLpro. Each of these molecules produced the binding energies of $-7.7$, $-7.655$, $-7.292$ and $-6.859$ kcal/mol, respectively (Table 4). The interactions between these antiviral compounds and the protein (PLpro) are depicted in Fig. 3, and the structural features of GRL0617 and the top four antiviral metabolites are listed in Table 5.

Consequently, after successively establishing the grid box with Glide’s Receptor Grid Generation tool in Maestro, the minimised 3D molecular structure of the co-crystallised inhibitor X77 was docked into the active site of viral Mpro. The molecular interaction of the co-crystallised inhibitor (X77) with the binding site of the viral protease SARS-CoV-2-Mpro was observed. The co-crystallised binding site appears to be engaged in a number of hydrogen bonding, Pi stacking and hydrophobic interactions. The non-covalent inhibitor X77 forms a hydrogen bond with Asn142, Gly143, Glu166 and His41. Furthermore, the ligand is sandwiched between the benzene ring of Phe140 and the imidazole ring of His172, forming a pi-pi connection with Cys145 and His41. Also hydrophobic interactions with different amino acids were observed including Thr25, Leu27, Ser144, Phe140, Leu141, His172, Leu167, Tyr54, His164, Gln189, Met165 and Pro168 within the active site.

The top four molecules from endophytes that showed to effectively bind with Mpro are cytonic acid B, cytonic acid A, asperphenalenone D and asperphenalenone A, respectively, with the binding energy of $-9.998$ kcal/mol, $-9.798$ kcal/mol, $-8.969$ kcal/mol and $-6.2417$ kcal/mol (Table 4). The compound with the best docking score, cytonic acid B, makes six hydrogen bonds with the amino acids, namely, Thr24, Thr26, Asn142, Glu166, Arg188 and Thr190; along with it forms Pi-anion interaction with Cys145. Moreover, hydrophobic interactions in the form of alkyl/pi-alkyl interaction with His41, Met49 and Met165 are being formed. Apart from these, Van der Waals interaction with this ligand is formed by 13 different amino acids as represented in Fig. 4. Cytonic acid A tends to form hydrogen bonds with Thr24, Asn142, Glu166 and Arg188, while alkyl/pi-alkyl interaction involves residues Cys44, Thr26, Met49 and Met165. Van der Waals interactions are also formed with several amino acid residues of the active site.

### Table 3

| Entry | Compound name        | Number of sites matched | Matched ligand sites | Phase screen score |
|-------|----------------------|-------------------------|----------------------|-------------------|
| 1     | Altertoxin V         | 4                       | A(1) A(2) R(12) R(-) R(13) | 1.522             |
| 2     | Epicocconigrone A    | 4                       | A(3) A(4) R(17) R(-) R(18) | 1.428             |
| 3     | Stachyborgisphenone B| 4                       | A(4) A(6) R(-) R(14) R(15) | 1.415             |
| 4     | Altertoxin II        | 4                       | A(2) A(3) R(12) R(-) R(11) | 1.39              |
| 5     | Alternariol 5-O-methyl ether | 4 | A(3) A(4) R(11) R(-) R(12) | 1.373             |
| 6     | Emodin-8-methyl ether | 4                        | A(4) A(1) R(10) R(-) R(11) | 1.314             |
| 7     | Emodin               | 4                       | A(4) A(3) R(11) R(-) R(10) | 1.303             |
| 8     | Altertoxin III       | 4                       | A(2) A(6) R(12) R(-) R(13) | 1.285             |
| 9     | Altertoxin I         | 4                       | A(2) A(4) R(13) R(-) R(12) | 1.252             |
| 10    | Griseoxanthone C     | 4                       | A(3) A(4) R(11) R(12) R(-) | 1.235             |
| 11    | Periolyrine          | 4                       | A(1) A(2) R(7) R(6) R(-) | 1.098             |
| 12    | Asperphenalenone A   | 4                       | A(6) A(1) R(23) R(-) R(22) | 1.094             |
| 13    | Asperphenalenone D   | 4                       | A(9) A(5) R(24) R(-) R(23) | 1.067             |
| 14    | Altertoxin VI        | 4                       | A(1) A(3) R(11) R(-) R(12) | 0.973             |
| 15    | Cytonic acids A      | 4                       | A(5) A(9) R(-) R(21) R(22) | 0.945             |
| 16    | Neosartoryadin B     | 4                       | A(3) A(4) R(-) R(16) R(17) | 0.939             |
| 17    | Neosartoryadin A     | 4                       | A(2) A(5) R(16) R(15) R(-) | 0.936             |
| 18    | Cytonic acid B       | 4                       | A(6) A(8) R(22) R(21) R(-) | 0.876             |

Ligands having Phase screen score above 0.5 are screened
site. The third best compound, based on the docking score, asperphenalenone D makes hydrogen bonds with five amino acids, namely, Thr25, Gly143, Cys145, Glu166 and Thr190. It forms hydrophobic interactions by making alkyl/pi-alkyl interaction with His41, Met49, Met165 and Pro168 along with making Van der Waals interactions with several amino acids in the active site of Mpro. Lastly, asperphenalenone D makes hydrogen bonds with His41, Asn119, Gly143, Cys145, and Met165. Like other ligands, this also makes Van der Waals interactions with several other amino acids in the active site of Mpro. The interactions between these antiviral compounds and the protein (Mpro) are depicted in Fig. 4. Moreover, the ligand properties of the reference inhibitors and top screened ligands of endophytic origins for both PLpro and Mpro are represented in Table 5.

**MM-GBSA analysis**

The interaction of a receptor and a ligand modifies the energies of both the free receptor and the ligand (ΔGBind); these energies also have a substantial influence on the stability of the receptor-ligand complex. In general, negative energy reflects a system’s greater stability. Table 4 shows the various energies produced by MM-GBSA for 7CMD with native ligand GRL0617, as well as the top four docking hits. In this case, the binding energies of GRL0617 with both 7CMD (−67.56 kcal/mol) are negative, indicating that the interactions are more spontaneous. Similarly, cytonic acid A is the most stable of the studied inhibitors, with a binding energy of −58.96 kcal/mol, while cytonic acid B is the second most stable, with a binding energy of −50.9 kcal/mol. The MM-GBSA energies of the remaining compounds examined were likewise negative, although the values were significantly higher, indicating a low occurrence rate for the complex.

The compound aspergilline E had the greatest docking score with SARS-CoV-2-PLpro; however, its ΔGBind energy (−50.81 kcal/mol) was determined to be greater than that of cytonic acid derivatives.

In a similar manner, for Mpro, considering the ΔGBind scores of reference compounds and ligands, the reference ligand X77 has the best ΔGBind score of −79.89 kcal/mol, while of all the other test ligands of endophytic origins, cytonic acid A has the best ΔGBind score of −75.30 kcal/mol, followed by cytonic acid B, asperphenalenone D and

| Compounds          | Glide score (kcal/mol) | Contributing binding residues                                                                 |
|--------------------|------------------------|-------------------------------------------------------------------------------------------------|
| **SARS-CoV-2-PLpro** |                        |                                                                                                 |
| GRL-0617 (control) | −6.441                 | ASP164, GLN269, TYR268, TYR264, PRO247, PRO248, LEU162, GLY163, ARG166, MET208, TYR273, GLY271, CYS270, THR301 |
| Aspergilline E     | −7.77                  | PRO247, TYR268, ASP164, GLY163, GLY271, TYR264, LEU162, TYR273, GLN269, GLY266, PRO248, ASN267, THR301, MET208 |
| Cytonic acid A     | −7.655                 | GLU161, GLU167, LEU162, GLY163, ASP164, GLN269, CYS270, TYR264, TYR268, GLY266, PRO248, ASN267, MET208, ARG166, PRO247, GLY271, LYS157 |
| Cytonic acid B     | −7.292                 | PRO247, PRO248, TYR273, ASN267, TYR264, GLU167, GLY266, GLY163, GLU161, LEU162, GLN269, ASP164, TYR268, MET208 |
| 4-Dehydroxyaltersolanol A | −6.859             | PRO247, PRO248, TYR273, ASP164, GLY163, GLN269, GLU167, LYS157, LEU162, TYR268, TYR264, THR301 |
| **SARS-CoV-2-Mpro** |                        |                                                                                                 |
| X77 (control)      | −8.52141               | MET49, ASP187, ARG188, PRO52, VAL42, CYS44, HIS41, THR25, LEU27, THR26, CYS145, ASN142, GLY143, SER144, HIS163, PHE140, LEU141, GLU166, HIS172, LEU167, TYR54, HIS164, GLN189, MET165, PRO168 |
| Cytonic acid B     | −9.998                 | HIS41, ASP187, GLY170, GLU166, LEU167, ALA191, GLN192, GLN189, THR190, PRO168, ARG188, MET165, CYL145, ASN142, MET49, THR25, THR24, SER46, LEU27, GLY143, HIS164, THR26, TYR54 |
| Cytonic acid A     | −9.798                 | CYS44, PRO52, MET49, TYR54, HIS41, ASN142, THR26, THR24, THR25, ASN119, GLY143, TYR118, LEU27, SER46, THR45, VAL42, GLU166, LEU167, PRO168, THR190, GLN192, ARG188, GLN189, HIS164, MET165, ASP187, ASP48 |
| Asperphenalenone D | −8.969                 | MET165, VAL186, HIS164, MET49, CYS44, THR45, SER46, THR25, THR24, GLY143, THR26, LEU27, CYL145, ASN142, SER144, GLN189, ASP187, PRO168, ALA191, THR190, LEU167, GLN192, ARG188 |
| Asperphenalenone A | −6.2417                | MET165, CYS44, ARG188, GLN189, MET49, ASN28, LEU27, VAL42, THR26, ASN119, GLY143, LEU141, TYR118, ASN142, THR25, THR24, SER46, HIS41, HIS163, SER144, CYL145, GLU166 |
Structural Chemistry (2022) 33:1619–1643

Two isomeric chemicals, cytonic acids A and B, previously reported as inhibitors of human cytomegalovirus protease (hCMV), were observed to produce docking scores and MM-GBSA energies for both PLpro and Mpro. As a result, both compounds were subjected to an MD simulations experiment to determine the stability of the protein–ligand combination for 100 ns. In addition to the test substance (cytonic acids A and B), simulations of GRL0617 with SARS-CoV-2-PLpro and X77 with SARS-CoV-2-Mpro were run as a control set for each protein.

The RMSD values for all the frames in the trajectory were determined once the MD simulation was completed. The RMSD value of any simulation, in general, indicates the changes during the simulation of specific atoms with respect to their original state. The docked pose of the protein–ligand complex was used as a baseline state or reference pose to compute the RMSD values. The RMSD value of protein atoms is represented by the Y-axis (left) in Figs. 5 and 6. The equilibration of the protein backbone for PLpro-GRL0617 (Fig. 5) occurs at an RMSD value of 2.3 ± 0.5 Å, whereas the equilibration of the protein backbone for Mpro-X77 (Fig. 6) occurs at an RMSD value of 2.2 ± 0.6 Å. For proteins that are bigger and non-globular in shape, the value might exceed beyond 4.0 Å. For the smaller and most globular proteins, RMSD value is ideally supposed to be in the limit of 1.0–4.0 Å. Here, the RMSD value after equilibration is not exceeding 4 Å for all the complexes under study at the peak end which is an advantageous parameter to screen the lead against the known ligand. For the complex of PLpro-cytonic acid A (Fig. 5), RMSD value remains within the accepted limits of 2.0 ± 0.5 Å considering the size of protein, whereas for PLpro-cytonic acid B, RMSD value is equilibrated at 2.3 ± 0.5 Å. Similarly for complexes Mpro-cytonic acid A and Mpro-cytonic acid B (Fig. 6), the protein backbone RMSD never exceeds 3.5 Å. In the graphs of Fig. 5 right Y-axis represents the ligand RMSD value. ‘Lig fit Prot’ signifies the RMSD values of ligand with reference to protein backbone. Throughout the whole simulation, ‘Lig fit Prot’ value of the PLpro-GRL0617 (Fig. 5) complex is in the range of 1.5 ± 0.5 Å, whereas for the PLpro-cytonic acid A complex this value is found to be 5.5 ± 1 Å. For, PLpro-cytonic acid B this value is 4.5 ± 1 Å which is slightly lower than that of cytonic acid A which suggests the relatively higher stability of the complex. On the other hand, ‘Lig fit Lig’ value of GRL0617 is lower than that of both cytonic acid isomers which suggests changes in the binding pose of ligand, but the difference is miniscule, hence negligible. Such results show that GRL0617 is having relatively higher stability compared to the tested ligand in binding pocket at the given docking pose. The ‘Lig fit Prot’ values for Mpro-cytonic acid A and Mpro-cytonic acid B the RMSD
values peak at 6.5 Å and 7.3 Å, respectively (Fig. 6). For all the ligands, the ‘Lig fit Prot’ implies that the interactions between protein and ligand are quite stable. Additionally, Figs. 7, 8, 9, 10, 11 and 12 provide pictorial insights onto the entire simulation results based on collected trajectories and 10,000 captured frameshifts.

Figure 7 represents the interactions made by reference ligand (GRL0617) and test compounds (cytonic acid A and cytonic acid B) with PLpro where the interaction types with percent interaction during 100-ns MD simulation run are represented. Similarly, for Mpro the interactions made by reference ligand (X77) and test compounds (cytonic acid A and cytonic acid B) are represented in Fig. 8. Figure 9 represents the interaction fraction of reference ligand (GRL0617) and test compounds (cytonic acid A and cytonic acid B) with PLpro while Fig. 10 represents the interaction fraction of reference ligand (X77) and test compounds (cytonic acid A and cytonic acid B) with Mpro. Hydrogen bonds, hydrophobic interactions such as Pi cation, pi-pi stacking, water bridges and ionic interactions made by ligand with

| Name of the Compounds                  | Structure | Molecular Weight | LogP | #Rotatable Bonds | #Acceptors | #Donors | Surface Area | Lipinski’s violation |
|----------------------------------------|-----------|------------------|------|-----------------|------------|---------|--------------|---------------------|
| GRL0617                                | ![GRL0617](image) | 304.393          | 4.22142 | 3               | 2          | 2       | 135.68       | 00                  |
| X77                                    | ![X77](image)  | 459.594          | 4.9392 | 6               | 4          | 2       | 200.565      | 00                  |
| Cytonic acid A                         | ![Cytonic acid A](image) | 580.63           | 6.2833 | 13              | 9          | 5       | 243.338      | 01                  |
| Cytonic acid B                         | ![Cytonic acid B](image) | 580.63           | 6.2833 | 13              | 9          | 5       | 243.338      | 01                  |
| Aspergilline E                         | ![Aspergilline E](image) | 502.52           | -0.8761 | 5               | 9          | 4       | 206.744      | 02                  |
| 4-dehydroxyaltersolanol A             | ![4-dehydroxyaltersolanol A](image) | 320.297         | -0.0471 | 1               | 7          | 4       | 130.993      | 00                  |
| Asperphenalenone D                    | ![Asperphenalenone D](image) | 654.797         | 6.08024 | 12              | 10         | 5       | 276.210      | 01                  |
| Asperphenalenone A                    | ![Asperphenalenone A](image) | 576.73           | 7.19174 | 12              | 7          | 5       | 247.767      | 01                  |
amino acids of proteins during 100-nS MD simulation are represented in these figures. Amongst this variety of interactions, ionic interactions were found to be absent in both control and test ligand. For all the graphs in Figs. 9 and 10, the stacked bar charts are normalised over the course of the trajectory; for example, a value of 0.7 suggests that 70% of the simulation time of the specific interaction is maintained. Values over 1.0 are possible as some protein residue may make multiple contacts of same subtype with the ligand. All the bar charts in Figs. 9 and 10 suggest all the ligands (reference inhibitor and test compounds) form strong interactions with several amino acids of PLpro and Mpro respectively. At several instances, the interaction fraction shoots above the value of 0.8, which shows strong interaction of ligand with that amino acid.

Protein–ligand interaction timeline ligands interacting with PLpro and Mpro are represented in Figs. 11 and 12 respectively. These diagrams show the instance of ligand interacting with a particular amino acid with respect to time and intensity. For instance, in Fig. 11, GRL0617 interacts with Pro248, Tyr264, Try268 and Gln269 strongly and evenly through the 100 ns of simulation. Similarly, cytonic acid A and cytonic acid B also interact with various amino acids such as Glu161, Leu162, Asp164, Pro248, Tyr264, Tyr268, Gln269 and Tyr273 effectively. Similarly in Fig. 12, X77 effectively interacts with His41, Asn142, Gly143, His163 and Glu166 of Mpro. Here like PLpro, cytonic acid A and cytonic acid B interact with various amino acids of Mpro during the MD simulation. Thus, from the evidence of docking, MM-GBSA and MD simulations, it can be deduced that cytonic acid A and cytonic acid B might serve as dual inhibitor of PLpro and Mpro.

Table 6 MM-GBSA binding free energy change profiles of ligands with SARS-CoV-2-PLpro and SARS-CoV-2-Mpro for docked complexes

| Ligand                          | $\Delta G$Bind (kcal/mol) | $\Delta G$Coulomb (kcal/mol) | $\Delta G$Hbond (kcal/mol) | $\Delta G$Lipo (kcal/mol) | $\Delta G$Packing (kcal/mol) | $\Delta G$vdW (kcal/mol) |
|--------------------------------|--------------------------|------------------------------|----------------------------|--------------------------|-----------------------------|--------------------------|
| **Ligands interacting with SARS-CoV-2-PLpro** |                          |                              |                            |                          |                             |                          |
| GRL0617 (control)              | $-67.5637$               | $-20.1695$                   | $-2.5442$                  | $-26.1400$               | $-3.1440$                   | $-46.3768$                |
| Aspergilline E                 | $-50.8186$               | $-17.1949$                   | $-1.24148$                 | $-18.2587$               | $-0.54685$                 | $-35.848$                 |
| Cytonic acid A                 | $-58.9626$               | $-34.7886$                   | $-2.45573$                 | $-20.7273$               | $-2.897$                   | $-42.5047$                |
| Cytonic acid B                 | $-55.6721$               | $-28.8001$                   | $-1.74414$                 | $-25.71$                 | $-3.10166$                 | $-52.1166$                |
| 4-Dehydroxyalter-solonol A     | $-38.3654$               | $-22.0615$                   | $-3.34432$                 | $-14.1614$               | $-1.84419$                 | $-31.2361$                |
| **Ligands interacting with SARS-CoV-2-Mpro** |                          |                              |                            |                          |                             |                          |
| X77 (control)                  | $-79.8911$               | $-35.3714$                   | $-1.8857$                  | $-17.6157$               | $-3.0805$                  | $-59.5617$                |
| Cytonic acid A                 | $-75.3087$               | $-36.7368$                   | $-4.0966$                  | $-16.7277$               | $-0.5834$                  | $-58.2717$                |
| Cytonic acid B                 | $-67.6847$               | $-41.9421$                   | $-3.7410$                  | $-13.1996$               | $-1.6820$                  | $-54.3987$                |
| Asperphenalenone D             | $-65.9103$               | $-24.9700$                   | $-2.4700$                  | $-16.5780$               | $-1.7280$                  | $-50.2750$                |
| Asperphenalenone A             | $-50.4602$               | $-10.6094$                   | $-1.8999$                  | $-11.8471$               | $-2.2800$                  | $-52.6731$                |

$\Delta G$Bind, Coulomb energy; $\Delta G$Hbond, hydrogen-bonding correction; $\Delta G$Lipo, lipophilic energy; $\Delta G$Packing, pi-pi packing correction; $\Delta G$vdW, Van der Waals energy

**Discussion**

Coronaviruses (CoVs) are diverse group of viruses that have potentials to infect various mammals including humans. These viruses have positive single strand of RNA as its genetic material. These CoVs have their structure architecture composed of proteins, namely, S-, E-, M- and N-protein. $\alpha$, $\beta$, $\gamma$ and $\delta$ are four genera into which these CoVs are distributed, whereby $\alpha$ and $\beta$ are the ones that have nag of infecting humans as their S-protein has structural complementary with human’s ACE-2 receptor, enabling these viruses to attach human cell surface ACE-2 which is a vital interaction to cause infection [36–38]. Similarly, $\gamma$ and $\delta$ CoVs have the tendency to infect Aves. As a reflection on the past, Middle East respiratory syndrome (MERS)-CoV and severe acute respiratory syndrome (SARS)-CoV deadly viruses belong to $\beta$ genera of CoVs; also, the current pandemic causing SARS-CoV-2 belongs to $\beta$ genera of CoVs. The recent variant Omicron that is ought to have very high infectivity is having high degree of mutations in S-protein which enables it to interact more efficiently with ACE-2; however, the target proteins used under present study, i.e. Mpro and PLpro, are identical with the previous variants of SARS-CoV-2; therefore, the research presented in this study is applicable to Omicron variant as well.

Aside from immunisation improvement with vaccine research, mainstream researchers have additionally given their energies and assets to distinguish intensifies that can counter the SARS-CoV-2 infection with alternative strategies [16, 39, 40]. Computationally driven molecular docking and MD recreations have been oftentimes used to identify compounds that possess potentials to interact with natural biochemistry of virus and halt its function [2, 41–43].
| Property                     | Model name       | Predicted values                  | Unit                                           |
|------------------------------|------------------|-----------------------------------|-----------------------------------------------|
| Absorption Water solubility  |                  | GRL0617 X77 Cytonic acid A -4.678 | Numeric (log mol/L)                           |
| Absorption CaCO₂ permeability|                  | GRL0617 X77 Cytonic acid B -2.878 | Numeric (log Papp in 10⁻⁶ cm/s)              |
| Absorption Intestinal absorption (human) |                | GRL0617 X77 Cytonic acid A -1.108 | Numeric (% absorbed)                         |
| Absorption Skin permeability |                  | GRL0617 X77 Cytonic acid B -2.902 | Numeric (log Kp)                              |
| Absorption P-glycoprotein substrate |                | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Absorption P-glycoprotein I inhibitor |            | GRL0617 X77 Cytonic acid A -2.639 | Categorical (yes/no)                         |
| Absorption P-glycoprotein II inhibitor |           | GRL0617 X77 Cytonic acid A -2.009 | Categorical (yes/no)                         |
| Distribution VDss (human)    |                  | GRL0617 X77 Cytonic acid A -2.914 | Numeric (% absorbed)                         |
| Distribution Fraction unbound (human) |            | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log Papp in 10⁻⁶ cm/s)              |
| Distribution BBB permeability |                  | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log Kp)                              |
| Distribution CNS permeability |                  | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log PS)                              |
| Metabolism CYP2D6 substrate  |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Metabolism CYP3A4 substrate  |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Metabolism CYP1A2 inhibitor  |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Metabolism CYP2C19 inhibitor |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Metabolism CYP2C9 inhibitor  |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Metabolism CYP1D6 inhibitor  |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Metabolism CYP3A4 inhibitor  |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Excretion Total clearance     |                  | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log ml/min/kg)                      |
| Excretion Renal OCT2 substrate |               | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Toxicity AMES toxicity        |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Toxicity Max. tolerated dose (human) |         | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log mg/kg/day)                      |
| Toxicity hERG I inhibitor     |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Toxicity hERG II inhibitor    |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Toxicity Oral rat acute toxicity (LD50) |       | GRL0617 X77 Cytonic acid A -2.914 | Numeric (mol/kg)                             |
| Toxicity Oral rat chronic toxicity (LOAEL) |     | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log mg/kg_bw/day)                   |
| Toxicity Hepatotoxicity       |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Toxicity Skin sensitisation   |                  | GRL0617 X77 Cytonic acid A -2.914 | Categorical (yes/no)                         |
| Toxicity T. pyriformis toxicity |               | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log ug/L)                           |
| Toxicity Minnow toxicity      |                  | GRL0617 X77 Cytonic acid A -2.914 | Numeric (log mM)                             |
Assortment of metabolites as potential drugs from bacteria, moulds, yeast and plants has been investigated to restrain the urgent viral target proteins as their natural availability makes them unfathomably accessible. For example, pyranonigrin A, flaviolin and sterenin M are some secondary metabolites screened from moulds which by molecular docking and MD recreation studies with Mpro are recommended that they can restrain the viral replication by means of associating with this protein [44–46]. Besides, there are plethora of examinations successfully completed and published with in silico workflow utilizing sub-atomic powerful MD reenactment and docking assays that are very helpful in various different everyday issues of biological sciences [47–51]. Furthermore, these in silico methodologies have additionally been used for strength appraisal of hydroxychloroquine against different expected target proteins of SARS-CoV-2 [52]. In these computational examinations, the reasoning is extremely fundamental that in the event that any of these metabolites serving as potential drug leads can intrude with the viral proteins, they can thwart the typical life pattern of the viral particle [53–55].

Endophytic microbes are symbiotically associated with plants and have been proven to produce novel or analogues of host bioactive metabolites exhibiting a variety of biological

---

Fig. 5 MD simulation protein–ligand interaction root-mean-square deviation (RMSD) profile of SARS-CoV-2-PLpro-cytonic acid A, SARS-CoV-2-PLpro-cytonic acid B and SARS-CoV-2-PLpro-GRL0617

Fig. 6 MD simulation protein–ligand interaction root-mean-square deviation (RMSD) profile of SARS-CoV-2-Mpro-cytonic acid A, SARS-CoV-2-Mpro-cytonic acid B and SARS-CoV-2-Mpro-X77
activities including antiviral activity [56, 57]. However, compounds of specifically endophytic origin are not explored against SARS-CoV-2. In the current study, 45 compounds that have been reported active against viruses such as influenza, H1N1, HIV, HCV, hCMV and EV-71 were retrieved through literature and screened through rigorous computation workflow. Top compounds obtained after docking and MM-GBSA analysis for each protease (PLpro and Mpro) are known to have antiviral activity against different viruses. Top ligands for both the proteins in the present study, cytonic acids A and B, are known to possess in vitro inhibitory activities towards hCMV protease with the IC$_{50}$ values of 43 µmol and 11 µmol, respectively. Both the cytonic acids were extracted from the fermented culture of endophytic

Fig. 7 Protein–ligand interaction diagram for PLpro showing percent of total time involved for particular interaction during molecular dynamics.

![Diagram of Protein–ligand interactions for PLpro](image)

- **Interactions**
  - Polar
  - Hydrophobic
  - Pi-Pi stacking
  - Hydrogen bond
  - Charged (negative)
  - Charged (positive)
fungus *Cytonaema* sp., which was isolated from the plant *Quercus* sp. (European oak) [58]. Other compounds interacting with Mpro are asperphenalenone A and asperphenalenone D, which were obtained from the ethyl acetate fraction of fermented culture of *Aspergillus* sp., an endophytic fungus isolated from the plant *Kadsura longipedunculata*. Asperphenalenone A and D displayed anti-HIV activity with IC_{50}s of 4.5 and 2.4 µM, respectively [59]. Aspergilline E was extracted along with aspergillines A–D from *Aspergillus versicolor*, an endophyte isolated from the plant *Paris*
*Polyphylla* var. *yunnanensis*, collected from China. Aspergil-
line E showed weak antiviral activity towards tobacco mosaic
virus with I$_{C_{50}}$ of 33.6 ± 3.0 µM [60]. In the present study,
it interacts with the PLpro with multiple interaction types.
Another compound having strong interaction with PLpro
is 4-dehydroxyaltersolanol A, which was obtained from
endophytic fungus *Nigrospora* sp. YE3033, harboured in
*Aconitum carmichaelii*. 4-Dehydroxyaltersolanol A displayed
in vitro antiviral activity towards H1N1 influenza A with
I$_{C_{30}}$ of 8.35 ± 1.41 µg/mL [61]. With all these evidences, it
is quiet insightful that cytonic acids A and B, asperphenale-
none A, asperphenalenone D and aspergilline E have antiviral
activities against different forms of viruses and could be of
potential against SARS-CoV-2; of course, in vitro assays are
needed to validate the findings, but such in silico study helps us to identify potential hits out of large pools of secondary metabolites and it is analogous of finding a purple wooden stick from the Amazon forest with ease.

The best docked compounds are cytonic acid A and cytonic acid B, which have significant interactions with both PLpro and Mpro proteases, according to the MD simulation studies. Considering the lack of treatment options for coronavirus infection, the current study proposes cytonic acids A and B as a dual inhibitor that interacts with critical amino acids in the binding site of PLpro and Mpro to inhibit their function, which could be useful in future in vitro and in vivo studies for COVID-19 therapeutics. Because we are dealing with infectious agents, in vitro validation of the suggested drugs mandates the use of Biosafety Level 4 (BSL4). Only an in silico investigation has been conducted. The
Fig. 11  Timeline representation of the interactions of ligand with amino acids for the complexes SARS-CoV-2-PLpro-cytonic acid A, SARS-CoV-2-PLpro-cytonic acid B and SARS-CoV-2-PLpro-GRL0617.
Fig. 12 Timeline representation of the interactions of ligand with amino acids for the complexes SARS-CoV-2-Mpro-cytonic acid A, SARS-CoV-2-Mpro-cytonic acid B and SARS-CoV-2-Mpro-X77.
information offered in this study will be beneficial to the scientific community. Even so, this work could potentially untap many more such exploratory work with endophytic compounds.

Acknowledgements We acknowledge Education Department, Government of Gujarat, India, for providing research fellowship to Rohit Patel and Priyashi Rao under the ScHeme Of Developing High quality research (SHODH), and also, University Grants Commission (UGC), New Delhi, India, for providing the fellowship award of ‘CSIR-NET Junior Research Fellowship (JRF)’ to Jignesh Prajapati. The authors are thankful to the Department of Microbiology and Biotechnology, School of Sciences, Gujarat University, DST-FIST Sponsored Department, for providing necessary facilities to perform experiments. We acknowledge GSBTM, DST, Government of Gujarat, for providing Bioinformatics Node facility and Finishing School support. We acknowledge GUJCOST, DST, Government of Gujarat, for the provision of supercomputing facility at the institute.

Author contribution J.P. and D.G. conceived and designed the experiments; J.P., R.P. and P.R. performed the experiments; J.P., R.P. and D.G. analysed the data and wrote the manuscript; R.R. and M.S. supervised the research and revised the manuscript. All authors discussed the manuscript critically for important intellectual content and approved the final version of the manuscript.

Funding This work was supported by Research Support Scheme (RSS) of Gujarat State Biotechnology Mission (GSBTM/ JD(R&D)/610/20–21/365–371).

Availability of data and material Library for the 3D structures of selected antiviral metabolites of endophyte origin is available from the corresponding author on reasonable request.

Prajapati, J., Patel, R., Rao, P., Saraf, M., Rawal, R. and Goswami, D. (2021). Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study. The work has been submitted as a Preprint at: https://www.researchsquare.com/article/rs-829046/v1

Declarations

Conflict of interest The authors declare no competing interests.

References

1. Shukla A, Parmar P, Kapoor G, Goswami D, Jha CK, Patel B, Saraf M (2021) Curse of La Corona: unravelling the scientific and psychological conundrums of the 21st century pandemic. Mol Divers (0123456789). https://doi.org/10.1007/s11030-020-10167-2
2. Fakhar Z, Khan S, AlOmar SY, Alkhurjii A, Ahmad A (2021) ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19. Sci Rep 11(1):1–15. https://doi.org/10.1038/s41598-020-79918-3
3. Filsinger M, Freitag M, Erhardt J, Wamsler S (2021) Rally around your fellows: information and social trust in a real-world experiment during the corona crisis. https://doi.org/10.1080/03623319.2021.1954463, 1–15. https://doi.org/10.1080/03623319.2021.1954463
4. Forni G, Mantovani A, Forni G, Mantovani A, Moretta L, Rappuoli R, Vines P (2021) COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28(2):626–639. https://doi.org/10.1038/s41418-020-00720-9
5. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO (2021) SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines 6(1). https://doi.org/10.1038/s41541-021-00292-w
6. Zahid MN, Moosa MS, Perna S, Buti EB (2021) A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacies. Arab Journal of Basic and Applied Sciences 28(1):225–233. https://doi.org/10.1080/25765299.2021.1903144
7. Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quin TP, Singh K (2021) Evolutionary analysis of the delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun 124(July):102715. https://doi.org/10.1016/j.jaut.2021.102715
8. Wang P, Nair MS, Liu L, Iketsani S, Luo Y, Guo Y, Ho DD (2021) Antibody resistance of SARS-CoV-2 variants B.1.1.7, B.1.351 and B.1.1.7. Nature 593(7857):130–135. https://doi.org/10.1038/s41586-021-03398-2
9. Gajjar ND, Dhameiliya TM, Shah GB (2021) In search of RdRp and Mpro inhibitors against SARS CoV-2: molecular docking, molecular dynamic simulations and ADMET analysis. J Mol Struct 1239. https://doi.org/10.1016/J.MOLSTRUC.2021.130488
10. Silva LR, da Silva Santos-Júnior PF, de Andrade Brandão J, Anderson L, Bassi ÉJ, Xavier de Araújo-Júnior J, da Silva-Júnior EF (2020) Druggable targets from coronaviruses for designing new antiviral drugs. Bioorg Med Chem 28(22). https://doi.org/10.1016/J.BMC.2020.115745
11. Nogara PA, Oming FB, Bolzan GR, Delgado CP, Aschner M, Orian L, Rocha JBT (2021) In silico studies on the interaction between Mpro and PLpro from SARS-CoV-2 and ebolens, its metabolites and derivatives. Mol Inf 40(8):2100028. https://doi.org/10.1002/MINF.202000028
12. Djokovic N, Ruzic D, Djikic T, Cvijic S, Ignotatovic J, Ibric S, Nikolic K (2021) An integrative in silico drug repurposing approach for identification of potential inhibitors of SARS-CoV-2 main protease. Mol Inf 40(5):2000187. https://doi.org/10.1002/MINF.202000187
13. Thomford NE, Senthelane DA, Rowe A, Munro D, Seple P, Maroyi A, Dzobo K (2018) Natural products for drug discovery in the 21st century: innovations for novel drug discovery. Int J Mol Sci 19(6). https://doi.org/10.3390/ijms19061578
14. Da A, Antonio S, Silvera L, Wiedemann M, Florêncio V, Florêncio Veiga-Júnior F (2020) Natural products’ role against COVID-19. RSC Adv 10(39):23379–23393. https://doi.org/10.1039/DORA03774E
15. Arora D, Sharma N, Singha Kampaneni V, Sharma V, Kushwaha M, Abrol V, Gupta P (2016) Isolation and characterization of bioactive metabolites from Xylaria psidii, an endophytic fungus of the medicinal plant Aegle marmelos and their role in mitochondrial dependent apoptosis against pancreatic cancer cells. Phytomedicine 23(12):1312–1320. https://doi.org/10.1016/j.phymed.2016.07.004
16. Messaoudi O, Gouzi H, El-Hoshouby AN, Benaceur P, Patel C, Goswami D, Bendahou M (2021) Berries anthocyanins as potential SARS-CoV-2 inhibitors targeting the viral attachment and replication; molecular docking simulation. Egypt J Pet 30(1):33–43. https://doi.org/10.1016/J.EJPE.2021.01.001
17. Rao P, Patel R, Shukla A, Parmar P, Rawal RM, Saraf M (2021) Identifying structural – functional analogue of GRL0617, the only well – established inhibitor for papain - like protease ( PLpro ) of SARS - CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation. Mol Divers (0123456789). https://doi.org/10.1007/s11030-021-10229-8
18. Dhameiliya TM, Nagar PR, Gajjar ND (2022) Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations. Mol Divers. https://doi.org/10.1007/S11030-022-10394-9
19. Nagar PR, Gajjar ND, Dhameiliya TM (2021) In search of SARS CoV-2 replication inhibitors: virtual screening, molecular
dynamics simulations and ADMET analysis. J Mol Struct 1246. https://doi.org/10.1016/J.MOLSTRUC.2021.131190
20. Hawas UW, El-Beih AA, El-Halawany AM (2012) Bioactive anti-rasquinones from endophytic fungus Aspergillus versicolor isolated from red sea algae. Arch Pharmacal Res 35(10):1749–1756. https://doi.org/10.1007/s12272-012-0100-x
21. Yang ZJ, Zhang YF, Wu K, Xu YX, Meng XG, Jiang ZT, Shao L (2020) New azaphilones, phomapenes A-C with biological activities from an endophytic fungus Phomopsis sp. CMMCC No.5416. Fitoterapia 145(March):104573. https://doi.org/10.1016/j.fitote.2020.104573
22. Hawas UW, Al-Farawati R, El-Kassem LTA, Turki AJ (2016) Different culture metabolites of the Red Sea fungus Fusarium equiseti optimize the inhibition of hepatitis C virus NS3/4A protease (HCV PR). Mar Drugs 14(10). https://doi.org/10.3390/md1410190
23. Arunpanichlert J, Rukchaisirikul V, Sukpondma Y, Phongsapich T, Seweartrakul S, Runghiandami N, Sakayaroj J (2010) Azaphilone and isocoumarin derivatives from the endophytic fungus Penicillium sclerotiorum PSU-A13. Chem Pharm Bull 58(9):1033–1036
24. Kumar BK, Faheem Sekhar KVGC, Ojha R, Prajapati VK, Pai A, Murugesan S (2020) Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. J Biomol Struct Dyn 0(0):1–24. https://doi.org/10.1080/07391070.2020.1824814
25. Rao P, Patel R, Shukla A, Parmar P, Rawal RM, Saraf M, Goswami D (2021) Identifying structural–functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation. Mol Diversity. https://doi.org/10.1007/s11030-021-10220-8
26. Fu Z, Huang B, Tang J, Liu S, Liu M, Ye Y, Huang H (2021) The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat Commun 12(1):1–12. https://doi.org/10.1038/s41467-020-20718-8
27. Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27(3):221–234. https://doi.org/10.1007/s10323-013-9446-8
28. Leach AR, Gillet VJ, Lewis RA, Taylor R (2010) Three-dimensional pharmacophore methods in drug discovery. J Med Chem 53(2):539–558. https://doi.org/10.1021/JM900187U
29. Sastry GM, Adzhigirey M, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234. https://doi.org/10.1007/s10323-013-9446-8
30. Dixon SL, Smodyrev AM, Rao SN (2006) PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 67(5):370–372. https://doi.org/10.1111/j.1747-0285.2006.00384.x
31. Wang W, Donini O, Reyes CM, Kollman PA (2001) Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu Rev Biophys Biomol Struct. https://doi.org/10.1146/annurev.biophys.30.1.1211
32. Wang J, Hou T, Xu X (2006) Recent advances in free energy calculations with a combination of molecular mechanics and continuum models. Current Computer Aided-Drug Design 2(3):287–306. https://doi.org/10.2174/157340906778226454
33. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Cheatham TE (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33(12):889–897. https://doi.org/10.1021/ar000033j
34. Massova I, Kollman PA (2000) Combined molecular mechanical and continuum solvent approach (MM- PBBSA/GBSA) to predict ligand binding. Perspect Drug Discovery Des. https://doi.org/10.1023/A:108763014207
35. Pires DEV, Blundell TL, Ascher DB (2015) pKCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072. https://doi.org/10.1021/jm5000104
36. Ren Z, Yan L, Zhang N, Guo Y, Yang C, Lou Z, Rao Z (2013) The newly emerged SARS-Like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like protease. Protein Cell 4(4):248–250. https://doi.org/10.1007/s11030-013-2841-3
37. Kumar A, Mehta R, Raj U, Varadwaj PK, Udayabanu M, Yennamalli RM, Singh TR (2018) Computational and in-vitro validation of natural molecules as potential acetylcholinesterase inhibitors and neuroprotective agents. Curr Alzheimer Res 16(2):116–127. https://doi.org/10.2174/1567205016661812155147
38. Yang H, Bartlam M, Rao Z (2006) Drug design targeting the main protease, the Achilles heel of coronaviruses. Curr Pharm Des 12(35):4573–4590. https://doi.org/10.2174/181620679010369
39. Pousoorfoosh A, Hashemipour H, Tüzün B, Pardakhty A, Mehrabani M, Nematollahi MH (2021) Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods. Biophys Chem 272(January):106564. https://doi.org/10.1016/j.bpc.2021.106564
40. Patel CN, Kumar SP, Pandya HA, Rawal RM (2021) Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation. Mol Diversity 25(1):421–433. https://doi.org/10.1007/s11030-020-10135-w
41. Guedes IA, Costa LSC, dos Santos KB, Karl ALM, Rocha GK, Teixeira IM, Dardenne LE (2021) Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. Sci Rep 11(1):1–20. https://doi.org/10.1038/s41598-021-84700-0
42. Basu A, Sarkar A, Maulti U (2020) Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. Sci Rep 10(1):1–15. https://doi.org/10.1038/s41598-020-74715-4
43. Murugan NA, Kumar S, Jeyakanthan J, Srivastava V (2020) Searching for target-specific and multi-targeting organisms for Covid-19 in the Drugbank database with a double scoring approach. Sci Rep 10(1):1–16. https://doi.org/10.1038/s41598-020-75762-7
44. Rao P, Shukla A, Parmar P, Rawal RM, Patel BV, Saraf M, Goswami D (2020) Proposing a fungal metabolite-flavivolin as a potential inhibitor of 3CLpro of novel coronavirus SARS-CoV-2 identified using docking and molecular dynamics. J Biomol Struct Dyn 0(0):1–13. https://doi.org/10.1080/07391102.2020.1813202
45. Prajapati J, Patel R, Goswami D, Saraf M, Rawal RM (2021) Sterein M as a potential inhibitor of SARS-CoV-2 main protease identified from MeFSAT database using molecular docking, molecular dynamics simulation and binding free energy calculation. Comput Biol Med 135:104568. https://doi.org/10.1016/j.compbiomed.2021.104568
46. Rao P, Shukla A, Parmar P, Rawal RM, Patel B, Saraf M, Goswami D (2020) Reckoning a fungal metabolite, pyranogirin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation. Biophys Chem 264:106425. https://doi.org/10.1016/j.bpc.2020.106425
47. Ton A-T, Gentile F, Hsing M, Ban F, Cherkasov A (2020) Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol Inf 39(8):2000028. https://doi.org/10.1002/mi.2000028
48. Alves VM, Bobrowski T, Melo-Filho CC, Korn D, Auerbach S, Schmitt C, Tropsha A (2021) QSAR modeling of SARS-CoV Mpro inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and
other drugs as candidates for repurposing against SARS-CoV-2. Mol Inf 40(1):2000113. https://doi.org/10.1002/MINF.202000113

49. Cavasotto CN, Di Filippo JI (2021) In silico drug repurposing for COVID-19: targeting SARS-CoV-2 proteins through docking and consensus ranking. Mol Inf 40(1):1–8. https://doi.org/10.1002/minf.202000115

50. Shukla A, Parmar P, Patel B, Goswami D, Saraf M (2021) Breaking bad: better call gingerol for improving antibiotic susceptibility of Pseudomonas aeruginosa by inhibiting multiple quorum sensing pathways. Microbiol Res 252:126863. https://doi.org/10.1016/j.microres.2021.126863

51. Rao P, Goswami D, Rawal RM (2021) Revealing the molecular interplay of curcumin as Culex pipiens acetylcholine esterase 1 (AChE1) inhibitor. Sci Rep 11(1):1–18. https://doi.org/10.1038/s41598-021-96963-8

52. Mukherjee S, Dasgupta S, Adhikari T, Adhikari U, Panja SS (2020) Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV2-2: inhibitor modelling study through molecular docking and MD-simulation study. J Biomol Struct Dyn 1–13. https://doi.org/10.1080/07391102.2020.1804458

53. Parmar P, Shukla A, Rao P, Saraf M, Patel B, Goswami D (2020) The rise of gingerol as anti-QS molecule: darkest episode in the LuxR-mediated bioluminescence saga. Bioorg Chem 99(March):103823. https://doi.org/10.1016/j.bioorg.2020.103823

54. Pandya PN, Kumar SP, Bhadresha K, Patel CN, Patel SK, Rawal RM, Mankad AU (2020) Identification of promising compounds from curry tree with cyclooxygenase inhibitory potential using a combination of machine learning, molecular docking, dynamics simulations and binding free energy calculations. Mol Simul 46(11):812–822. https://doi.org/10.1080/08927022.2020.1764552

55. Goswami D (2021) Comparative assessment of RNA-dependent RNA polymerase (RdRp) inhibitors under clinical trials to control SARS-CoV2 using rigorous computational workflow. RSC Adv 11(46):29015–29028. https://doi.org/10.1039/d1ra04460e

56. Prajapati J, Goswami D, Rawal RM (2021) Endophytic fungi: a treasure trove of novel anticancer compounds. Current Research in Pharmacology and Drug Discovery 100050. https://doi.org/10.1016/j.crphar.2021.100050

57. Manganyi MC, Ateba CN (2020) Untapped potentials of endophytic fungi: a review of novel bioactive compounds with biological applications. Microorganisms 8(12):1–25. https://doi.org/10.3390/microorganisms8121934

58. Guo B, Dai JR, Ng S, Huang Y, Leong C, Ong W, Carté BK (2000) Cytonic acids A and B: novel tridepside inhibitors of hCMV protease from the endophytic fungus Cytonaema species. J Nat Prod 63(5):602–604. https://doi.org/10.1021/np990467r

59. Pang X, Zhao JY, Fang XM, Zhang T, Zhang DW, Liu HY, Yu LY (2017) Metabolites from the plant endophytic fungus Aspergillus sp. CPCC 400735 and their anti-HIV activities. J Nat Prod 80(10):2595–2601. https://doi.org/10.1021/acs.jnatprod.6b00878

60. Zhou M, Miao M-M, Du G, Li X-N, Shang S-Z, Zhao W, Gao X-M (2014) Aspergilloses A–E, highly oxygenated hexacyclic indole–tetrahydrofuran–tetramic acid derivatives from Aspergillus versicolor. https://doi.org/10.1021/ol502307a

61. Zhang SP, Huang R, Li FF, Wei LX, Fang XW, Xie XS, He J (2016) Antiviral anthraquinones and azaphilones produced by an endophytic fungus Nigrospora sp. from Aconitum carmichaeli. Fitoterapia 112:85–89. https://doi.org/10.1016/j.fitote.2016.05.013

62. Qin C, Lin X, Lu X, Wan J, Zhou X, Liao S, Liu Y (2014) Sesquiterpenoids and xanthones derivatives produced by sponge-derived fungus Stachybotry sp. HH1 ZSD51F1–2. The Journal of Antibiotics advance online publication. https://doi.org/10.1038/ja.2014.97

63. Zhang G, Sun S, Zhu T, Lin Z, Gu J, Li D, Gu Q (2011) Antiviral isoindolone derivatives from an endophytic fungus Emericella sp. associated with Aegiceras corniculatum. Phytochemistry 72(11–12):1436–1442. https://doi.org/10.1016/j.phytochem.2011.04.014

64. Liu L, Liu S, Jiang L, Chen X, Guo L, Che Y (2008) Chloropukenepanin, the first chlorinated pukenepane derivative, and its precursors from Pestalotiopsis fici. Org Lett 10(7):1397–1400. https://doi.org/10.1021/ol800113t

65. Zhang D, Tao X, Liu J, Chen R, Zhang M, Li L, Dai J (2016) Periconiasin G, a new cytochalasin with unprecedented 7/6/5 tricyclic ring system from the endophytic fungus Periconia sp. https://doi.org/10.1016/j.tetlet.2016.01.030

66. Bashyal BP, Wellsensiek BP, Ramakrishnan R, Faeth SH, Ahmad N, Gunatilaka AAL (2014) Altertoxins with potent anti-HIV activity from Alternaria tenuissima QUE1Se, a fungal endophyte of Quercus emoryi. Bioorg Med Chem 22(21):6112–6116. https://doi.org/10.1016/j.bmc.2014.08.039

67. Ding L, Münch J, Goerls H, Maier A, Fiebig HH, Lin WH, Hertweck C (2010) Xiamycin, a pentacyclic indolosesquiterpene with selective anti-HIV activity from Alternaria tenuissima QUE1Se, a fungal endophyte of Quercus emoryi. Bioorg Med Chem 22(21):6112–6116. https://doi.org/10.1016/j.bmc.2014.08.039

68. Yu G, Zhou G, Zhu M, Wang W, Zhu T, Gu Q, Li D (2016) Neosartoryadins A and B, fumiquinazoline alkaloids from a mangrove-derived fungus Neosartorya udagawae HDN13-313. Org Lett 18(5):2905–2908. https://doi.org/10.1021/acs.orglett.5b02964

69. Ding J, Zhao J, Yang Z, Ma L, Mi Z, Wu Y, Cen S (2017) Microbial natural product alternariol 5-O-methyl ether inhibits HIV-1 integration by blocking nuclear import of the pre-integration complex. Viruses 9(5):1–14. https://doi.org/10.3390/v9050105

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.